gremubamab

Gremubamab is a first-in-class, bivalent, bispecific human immunoglobulin G1 kappa monoclonal antibody designed to target *Pseudomonas aeruginosa* infections. It selectively binds to two key virulence factors of *P. aeruginosa*: the PcrV protein (a component of the type III secretion system involved in host cell cytotoxicity) and the Psl exopolysaccharide (involved in bacterial colonization and tissue adherence). By targeting both these antigens, gremubamab aims to enhance neutrophil-mediated killing of *P. aeruginosa* and prevent associated cytotoxicity. The drug was developed primarily for prevention and treatment of nosocomial pneumonia (including ventilator-associated pneumonia) and bronchiectasis with chronic or high-risk *Pseudomonas* infection. Clinical development included phase 1 and phase 2 trials; however, further development for nosocomial pneumonia was discontinued due to safety/efficacy reasons.

Other names

Anti-Psl/PcrV